BOAN BIOTECH (06955) Shareholder Transfers Shares from China Securities Depository and Clearing Hong Kong to CITIC SEC Brokerage Hong Kong, Portfolio Value of HK$346 Million

Stock News01-27 08:56

According to the latest data from the Hong Kong Stock Exchange, on January 26, a shareholder of BOAN BIOTECH (06955) transferred shares from China Securities Depository and Clearing Hong Kong to CITIC SEC Brokerage Hong Kong. The transferred portfolio was valued at HK$346 million, representing a 6.32% stake.

BOAN BIOTECH announced that the company's board of directors has been notified by its controlling shareholder, Luye Pharma Group, that, pursuant to the terms of the subscription agreement related to exchangeable preferred shares, it plans to arrange for its wholly-owned subsidiary, Shandong Luye Pharmaceutical Co., Ltd., to complete a proposed transfer of an additional 11.9866 million H shares to the issuer on the market by January 27, 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1123106870?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-27 08:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1123106870","market":"hk","top_or_hot":-1,"title":"BOAN BIOTECH (06955) Shareholder Transfers Shares from China Securities Depository and Clearing Hong Kong to CITIC SEC Brokerage Hong Kong, Portfolio Value of HK$346 Million","media":"Stock News","content":"<p>According to the latest data from the Hong Kong Stock Exchange, on January 26, a shareholder of BOAN BIOTECH (06955) transferred shares from China Securities Depository and Clearing Hong Kong to CITIC SEC Brokerage Hong Kong. The transferred portfolio was valued at HK$346 million, representing a 6.32% stake.</p>\n<p>BOAN BIOTECH announced that the company's board of directors has been notified by its controlling shareholder, Luye Pharma Group, that, pursuant to the terms of the subscription agreement related to exchangeable preferred shares, it plans to arrange for its wholly-owned subsidiary, Shandong Luye Pharmaceutical Co., Ltd., to complete a proposed transfer of an additional 11.9866 million H shares to the issuer on the market by January 27, 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BOAN BIOTECH (06955) Shareholder Transfers Shares from China Securities Depository and Clearing Hong Kong to CITIC SEC Brokerage Hong Kong, Portfolio Value of HK$346 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBOAN BIOTECH (06955) Shareholder Transfers Shares from China Securities Depository and Clearing Hong Kong to CITIC SEC Brokerage Hong Kong, Portfolio Value of HK$346 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-27 08:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>According to the latest data from the Hong Kong Stock Exchange, on January 26, a shareholder of BOAN BIOTECH (06955) transferred shares from China Securities Depository and Clearing Hong Kong to CITIC SEC Brokerage Hong Kong. The transferred portfolio was valued at HK$346 million, representing a 6.32% stake.</p>\n<p>BOAN BIOTECH announced that the company's board of directors has been notified by its controlling shareholder, Luye Pharma Group, that, pursuant to the terms of the subscription agreement related to exchangeable preferred shares, it plans to arrange for its wholly-owned subsidiary, Shandong Luye Pharmaceutical Co., Ltd., to complete a proposed transfer of an additional 11.9866 million H shares to the issuer on the market by January 27, 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0183","symbol_name":"MSCI概念","start_time":0,"source_url":"","article_id":"1123106870","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1123106870","pubTimestamp":1769475381,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"According to the latest data from the Hong Kong Stock Exchange, on January 26, a shareholder of BOAN BIOTECH (06955) transferred shares from China Securities Depository and Clearing Hong Kong to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"161027":"证券","600030":"中信证券","BK0183":"MSCI概念","BK0188":"融资融券","BK0012":"证金概念","LU2289578879.USD":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","BK1564":"中资券商股","LU1997245177.USD":"安联神洲A股基金","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","BK0028":"国家队","BK0276":"资本市场","LU1720050803.USD":"安联全方位中国股票基金","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","BK1161":"生物科技","06030":"中信证券","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC","BK1516":"腾讯概念","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","BK1147":"投资银行业与经纪业","BK0196":"行业龙头","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","BK1521":"挪威政府全球养老基金持仓","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","06955":"博安生物"},"translate_title":"博安生物(06955)股东从中国证券登记结算香港转让股份至中信证券经纪香港，组合价值3.46亿港元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"161027":1,"600030":1,"06955":1,"06030":1},"content_text":"According to the latest data from the Hong Kong Stock Exchange, on January 26, a shareholder of BOAN BIOTECH (06955) transferred shares from China Securities Depository and Clearing Hong Kong to CITIC SEC Brokerage Hong Kong. The transferred portfolio was valued at HK$346 million, representing a 6.32% stake.\nBOAN BIOTECH announced that the company's board of directors has been notified by its controlling shareholder, Luye Pharma Group, that, pursuant to the terms of the subscription agreement related to exchangeable preferred shares, it plans to arrange for its wholly-owned subsidiary, Shandong Luye Pharmaceutical Co., Ltd., to complete a proposed transfer of an additional 11.9866 million H shares to the issuer on the market by January 27, 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1123106870","isCrawlerRequest":true}